BioRxiv: High-throughput mapping of 6,888 RAD51D variants identifies distinct biochemical functions needed for homologous recombination and olaparib response (Sung)
January 30, 2026
Kristie E. Darrah, Shelby L. Hemker, Yashpal Rawal, Noah J. Goff, Phoebe Parker, Gayatri Ganesan, Caleb M. Stratton, Katherine Oppenheimer, Ella Roberts, Elena Glick, Nicole Banks, Arjun Kumar, Silvia Casadei, Matthew W. Snyder, Katherine Nathanson, Susan M. Domchek, Lea M. Starita, Shaun K. Olsen, Patrick Sung, Jacob O. Kitzman, Kara A. Bernstein Summary The tumor suppressor RAD51D is essential for homologous recombination (HR). Pathogenic variants in RAD51D are associated with breast and ovarian cancers. However, most clinical missense variants are of unknown significance. We performed a multiplex assay of variant effect to test 6,888 RAD51D coding variants for loss-of-function. The resulting variant-to-function [...]